利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.027 秒)

    Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
    2.
    发明申请
    Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin 审中-公开
    包含头孢菌素的纳米颗粒和控释组合物

    公开(公告)号：US20090269400A1

    公开(公告)日：2009-10-29

    申请号：US11568825

    申请日：2006-05-16

    申请人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    发明人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/10 ,  A61K9/14 ,  A61K9/50 ,  A61P19/10 ,  A61K31/545 ,  A61K31/546

    CPC分类号： A61K9/14 ,  A61K9/1676 ,  A61K9/5078

    摘要： The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix.

    摘要翻译： 本发明涉及包含具有改善的生物利用度的纳米颗粒抗生素的组合物。 优选地，抗生素包含有效平均粒度小于约2000nm的纳米微粒头孢菌素颗粒，并且可用于治疗细菌感染。 本发明还涉及包含头孢菌素或纳米微粒头孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物用于治疗细菌感染。 纳米颗粒头孢菌素颗粒可以配制成控释药物递送系统，由此颗粒用一种或多种天然或合成的亲水或疏水性聚合物涂层材料涂覆一次或多次，或分散在整个天然或合成的亲水和/或疏水性聚合物基质中 。

    Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists
    7.
    发明申请
    Treatment of Gastroparesis and Nonulcer Dyspepsia With GABAB Agonists 审中-公开
    用GABAB激动剂治疗胃轻瘫和消化不良消化不良

    公开(公告)号：US20090246233A1

    公开(公告)日：2009-10-01

    申请号：US12480287

    申请日：2009-06-08

    申请人： John Devane ,  Jackie Butler

    发明人： John Devane ,  Jackie Butler

    IPC分类号： A61K9/00 ,  A61K31/195 ,  A61P1/00

    CPC分类号： A61K31/195 ,  A61K9/0004 ,  A61K9/2846 ,  A61K9/7023

    摘要： The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and formulations are especially suitable for treating gastroparesis and nonulcer dyspepsia.

    摘要翻译： 本发明涉及包含治疗有效量的巴氯芬或（R） - 巴氯芬或其药学上可接受的盐的制剂及其使用方法。 本发明的制剂和方法被设计为以最大化其治疗效果的方式释放治疗量的巴氯芬。 方法和制剂特别适用于治疗胃轻瘫和非溃疡性消化不良。

    Chronotherapeutic compositions and methods of their use
    8.
    发明申请
    Chronotherapeutic compositions and methods of their use 审中-公开
    计时组合物及其使用方法

    公开(公告)号：US20060003001A1

    公开(公告)日：2006-01-05

    申请号：US11053865

    申请日：2005-02-10

    申请人： John Devane ,  Jackie Butler

    发明人： John Devane ,  Jackie Butler

    IPC分类号： A61K31/137 ,  A61K9/22

    CPC分类号： A61K31/138 ,  A61K9/1676 ,  A61K9/5078 ,  A61K31/137 ,  A61K31/165

    摘要： Chronotherapeutic formulations of cardiovascular drugs are disclosed. The formulations comprise at least one cardiovascular drug that exhibits an in vivo elimination half-life of less than about 8 hours; wherein the formulation exhibits the following in vivo profile following administration to a subject: a) a delay in release of therapeutic levels of the at least one drug for about 2 to about 8 hours; b) a Tmax at about 8 to about 12 hours; c) a drug plasma level within 50% of the peak for greater than or equal to 12 hours; and d) a peak-to-trough ratio of drug plasma levels greater than or equal to about 4.

    摘要翻译： 公开了心血管药物的治疗剂型。 该制剂包含至少一种显示体内消除半衰期小于约8小时的心血管药物; 其中所述制剂在施用于受试者后表现出以下体内特征：a）所述至少一种药物的治疗水平的释放延迟约2至约8小时; b）约8至约12小时的T max max; c）药物血浆水平在峰值的50％以内大于或等于12小时; 和d）药物血浆水平的峰 - 谷比大于或等于约4。

    Modified release formulations and methods of treating inflammatory bowel disease
    9.
    发明授权
    Modified release formulations and methods of treating inflammatory bowel disease 有权
    改善释放制剂和治疗炎性肠病的方法

    公开(公告)号：US07825106B2

    公开(公告)日：2010-11-02

    申请号：US11371958

    申请日：2006-03-10

    申请人： John Devane ,  Jackie Butler

    发明人： John Devane ,  Jackie Butler

    IPC分类号： A61K31/60 ,  A61K31/603 ,  A61K31/606 ,  A61K31/609 ,  A61K31/612 ,  A61K31/616 ,  A61K31/618 ,  A61K31/625

    CPC分类号： A61K9/2054 ,  A61K9/2031 ,  A61K31/60 ,  A61K31/606 ,  A61K31/655 ,  C07C245/08 ,  C07C251/84

    摘要： Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

    摘要翻译： 公开了治疗炎症性肠病的方法和制剂。 方法和制剂包括但不限于用于将有效浓度的4-氨基水杨酸和/或5-氨基水杨酸及其药学上可接受的盐和前药递送到受影响的肠的区域的方法和制剂，即 ，远端肠道 方法和制剂包含修饰释放元件，提供药物递送到受影响的或期望的区域。 可用本发明治疗的疾病和病症包括克罗恩病和溃疡性结肠炎。